Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the adult population
worldwide. This pathology can progress into end-stage liver disease with life-threatening …

Peptides have unique characteristics that make them highly desirable as therapeutic agents.
The physicochemical and proteolytic stability profiles determine the therapeutic potential of …

The oral delivery of peptide therapeutics could facilitate precision treatment of numerous
gastrointestinal (GI) and systemic diseases with simple administration for patients. However …

Introduction Biomacromolecules have proven to be an attractive choice for treating diseases
due to their properties of strong specificity, high efficiency, and low toxicity. Besides greatly …

Human serum albumin (hSA) is the major carrier protein for fatty acids (FAs) in plasma. Its
ability to bind multiple FA moieties with moderate to high affinity has inspired the use of FA …

Peptides, an emerging modality within the biopharmaceutical industry, are often delivered
subcutaneously with evolving prospects on oral delivery. Barrier biology within the subcutis …

This paper reviews many of the properties of a peptide that need to be considered prior to
development as an oral dosage form when co-formulated with a permeation enhancer to …

Sodium caprate (C10) has been widely evaluated as an intestinal permeation enhancer for
the oral delivery of macromolecules. However, the effect of C10 on the intestinal absorption …

Background Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the
treatment of diabetes, its large molecular weight and high hydrophilicity result in poor …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve
glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors …